BEIJING: Insulin glargine injections developed by Chinese pharmaceutical company has been approved for diabetes patients in Pakistan. Insulin glargine injecta BASAGINE developed received approval for registration (Reg. No. 111178) by Drug Regulatory Authority of Pakistan (DRAP), China Economic Net (CEN) reported.

According to company, it is first insulin glargine injection (prefilled injection pen) biosimilar drug in Pakistan. Insulin glargine injection is an essential long-acting insulin analogue product in treatment of diabetes for its efficacy and safety.

In Pakistan, 33 million people aged 20-79 were living with diabetes in 2021, ranking third in world after China and India. Prevalence of diabetes among adults aged 20-79 in Pakistan is 30.8 percent, highest in world, as per latest data released by International Diabetes Federation (IDF) Global Diabetes Overview 10th Edition (2021).

“Since 2010, pharmaceutical trade between China and Pakistan has maintained good momentum. As China eases its Covid restriction, we believe that this momentum will continue to strengthen”, company added.

Published in The Daily National Courier, January, 14 2023

Like Business on Facebook, follow @DailyNCourier on Twitter to stay informed and join in the conversation.